Abstract Hematopoietic stem cell transplantation is an effective approach for the treatment of severe combined immunodeficiency (SCID). However, SCID is not a homogeneous disease, and the treatment required for successful transplantation varies significantly between SCID subtypes and the degree of HLA mismatch between the best available donor and the patient. Recent studies are beginning to more clearly define this heterogeneity and how outcomes may vary. With a more detailed understanding of SCID, new approaches can be developed to maximize immune reconstitution, while minimizing acute and long-term toxicities associated with chemotherapy conditioning.
Introduction
For patients with severe combined immunodeficiency (SCID), there are several treatment options. Hematopoietic stem cell transplantation (HSCT) is potentially curative for all patients with SCID. Gene therapy (GT) may also be curative and currently is available on an experimental basis for eligible patients with IL2RG and adenosine deaminase deficiency (ADA) SCID (see Calero et al., review in this series). Finally, enzyme replacement therapy (ERT) is supportive therapy for patients with ADA-SCID and is often used while awaiting HSCT or GT. For the majority of patients meeting the diagnostic criteria for SCID [1, 2 • ], HSCT offers the most widely available approach to an effective cure and will be the focus of this chapter. SCID is a rare disease with an incidence of 1:58000 [3] and most centers treating patients with SCID only see on average one patient per year. Thus, it is very difficult if not impossible for any single center to develop optimal treatment approaches for this disorder. The Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplant (EBMT) has brought together centers in Europe to perform retrospective studies of SCID and other primary immune deficiencies (PIDs) and develop guidelines for therapy. Until recently, this collaborative effort was not available in North America. The Primary Immune Deficiency Treatment Consortium (PIDTC) is an NIH/NIAID/ORDR-funded group of 43 centers in North America established in 2009 to study the definitive treatment of PIDs, specifically SCID, Chronic Granulomatous Disease and Wiskott-Aldrich Syndrome [4] . Many of the recent advances in our understanding of the diagnosis of SCID and issues surrounding treatment for SCID are a result of IEWP/EBMT and PIDTC studies. These issues and their effects on immunologic and survival outcomes are discussed below. Specific considerations for SCID subtypes are outlined in Table 1 .
Timing of HSCT
In general, SCID patients who proceed to HSCT earlier in life have superior outcomes compared to those transplanted This article is part of the Topical Collection on Immunology.
later [5] [6] [7] . The PIDTC recently performed a retrospective analysis of the largest cohort of SCID patients in North America published to date [8 •• ] . In this study, the likelihood of having an active infection at the time of transplant was significantly higher (52 %) for patients transplanted at [3.5 months of age (old), compared to those transplanted at \3.5 months of age (young) (22 %) . Old infants with active infection had significantly (p \ 0.001) poorer 5-year survival (50 %) versus young infants with/without infection (94 %), old infants with no infection (90 %), or infants whose infection cleared by the time of HSCT (82 %).
The widespread use of newborn screening (NBS) by T cell receptor excision circle (TREC) quantification has greatly shortened time to diagnosis, making treatment possible at a very early age [3, 9, 10 ] (see Kwan et al., review in this series). In one prospective study, patients Table 1 SCID subtypes and relevant considerations for HSCT   T-B?NK-IL2RG, JAK3 Generally reconstitute T cell immunity from any type of donor without any conditioning required When using donors other than matched siblings, usually fail to regain B cell function, unless conditioning is provided Increased risk of late HPV infection, which is likely related to abnormal cc/JAK3-dependent signaling in keratinocytes [41] Gene therapy (GT) is being evaluated in IL2RG-deficient patients T-B-NK-ADA When a MSD is not available, enzyme replacement therapy (ERT) is a potential option and should be pursued over a mismatched unrelated HSCT [26] The underlying defect in purine metabolism may lead to increased susceptibility to certain chemotherapeutic agents, which may explain why survival is lower in those patients getting conditioning [26] Matched related or unrelated donors may not require a conditioning regimen [12 • ]. For mismatched related or unrelated donors, most centers have used a conditioning regimen, as rejection is seen more commonly without conditioning in these transplants compared to IL2RG-deficiency patients, despite absence of NK cells [52] B cell function is often recovered after matched sibling donor transplant, even without conditioning, but is more variable in unconditioned unrelated donors or mismatched related donors [ In patients with RAG1 or RAG2-SCID, there is no increased sensitivity to alkylating chemotherapy as seen in defects of DNA repair [42] For donors other than MSDs, there is an increased risk of rejection if no conditioning is used [7, 13] For donors other than MSD's, there is very poor B cell recovery if conditioning is not used Hypomorphic mutations typically require conditioning, regardless of donor type
T-B-NK?
Artemis DNA repair defects are reviewed elsewhere [27] If maternal engraftment is present, a maternal donor is strongly preferred, since T-cell engraftment will generally occur without the need for alkylating chemotherapy High rate of regimen-related toxicity and late effects when DNA-damaging agents are used [42, 54] In order to avoid alkylating therapy, it is advisable to proceed with an unconditioned transplant, even with haploidentical or matched unrelated donors. If conditioning is used, attempts to minimize the number of alkylators and the dosing are recommended B cell recovery is rare if conditioning is not used
Reduced intensity conditioning that includes fludarabine may be used if rejection occurs following unconditioned HSCT [13] T-B?NK?
DNA ligase IV, Cernunnos-XLF,
DNA-PKcs
The number of patients with other radiation sensitive defects is too small for survival analysis [15] . An advantage of using conditioning, particularly in uninfected patients, is the increased chance of achieving donor myeloid chimerism (62 vs 20 %, p = 0.007), and being off immunoglobulin replacement therapy in patients surviving beyond 2 years post-HSCT (O.R. of 8.9; 84 vs 41 %,
Overall, the highest rates of B cell function have consistently been observed in studies using myeloablative conditioning (MAC) [16, 17, 18 • ].
While not absolutely necessary for T cell reconstitution, myeloid chimerism is also known to strongly predict recovery of thymic function as measured by both TREC levels and CD45RA? circulating T cells, which reflect thymopoiesis and T cell receptor (TCR) diversity [19, 20] . This was observed in a subset of PIDTC study patients analyzed for naïve CD4 ? CD45RA ? reconstitution; 100 % of patients who received conditioning developed naive T cells[100/lL, but this was less common in those who did not receive conditioning (approximately 50 %) [8 •• ] . In addition, the use of a conditioning regimen was associated with an 8.8-fold increased chance of attaining a CD3 count [1,000/mm 3 at 2-5 years (89 vs 62 %, p = 0.007) [8 •• ] . However, in some SCID subtypes (i.e., IL2RG and ADA defects), T cell recovery appears to be equivalent in MSD versus URD transplants even without the use of conditioning [12 • ].
In terms of which chemotherapy agents are most optimal for SCID patients who may require conditioning, there are several options. Busulfan-based regimens are most commonly used in both reduced intensity (RIC) and myeloablative (MAC) transplants for SCID, although alternatives, i.e., melphalan-based regimens, have been used with comparable results [8 •• ] . Melphalan has been used successfully in a reduced intensity regimen, although metabolism of melphalan in infants is not well defined, and should be used with caution, if at all, in patients\6 months of age (P. Veys, personal communications, European group for Blood and Marrow Transplant guidelines) [21, 22] . Treosulfan (not yet approved in the US), which is associated with less venoocclusive disease and CNS toxicity than busulfan, has also been used in infants, although its metabolism in this age has not been well studied [22] . Fludarabine is often used in combination with alkylating agents to provide T lymphocyte ablation, but it may not be sufficient to fully eradicate host NK cells in mismatched HSCT and should be used with some care in infants\6 months of age [23] .
Serotherapy (anti-thymocyte globulin [ATG] or alemtuzumab [CAMPATH-1H]) is also frequently administered prior to stem cell infusion as part of conditioning, with or without chemotherapy. With its relatively long half-life, serotherapy provides host immunoablation (reducing the risk of rejection), as well as GVHD prophylaxis. Serotherapy with post-HSCT GVHD prophylaxis is essential in URD transplants for SCID patients to reduce the incidence and severity of GVHD [12 • ]. It may be used in combination with ex vivo T cell depletion (TCD) prior to haploidentical HCT, but the dosing must be carefully considered to avoid prolonged T cell recovery [24] .
In summary, the use of conditioning remains controversial. It is clearly associated with poorer survival in patients with infection at the time of HSCT [8 •• ] , and the safety in uninfected patients is not fully established. While it may result in enhanced T and B cell reconstitution, this may be at the cost of early toxicity and late effects, a question which has not been carefully studied.
Donor Selection
An approach at our center at UCSF for determining the most appropriate donor and conditioning regimen for patients with SCID is outlined in Fig. 1 . Regardless of SCID type, all siblings should be HLA typed as soon as the diagnosis is made. Because of the high incidence of shared HLA haplotypes within some SCID populations and the potential need for haploidentical donors, parents should also be typed.
Matched Sibling Donors
An HLA-matched sibling is the donor of choice for all SCID types. In the 2014 PIDTC analysis, for patients receiving a MSD transplant, 5-year survival far exceeded that of any other donor type, at 97 % [8
For patients with typical SCID (T cells \300/lL and T cell function \10 % lower limit of normal) [2 • ], most centers do not use a conditioning regimen for MSD transplants, regardless of SCID type, as the risk of rejection and severe GVHD are quite low. As shown in Table 2 , excellent survival rates have been observed in studies where a conditioning regimen was not used, ranging from 89 to 95 % [7, 12 • , 25] . Even if maternally engrafted cells are present, eradication of these cells prior to unconditioned MSD HSCT is not necessary [12 • ]. Generally, for MSD, conditioning is only required for patients with reticular dysgenesis, leaky SCID (T cells\1,000/lL, T cell function \30 % lower limit of normal, and absence of maternal engraftment) or Omenn syndrome, which often requires some degree of myeloablation to correct the associated inflammatory and autoimmune manifestations, regardless of donor type. To date, there are no data comparing conditioned vs unconditioned HSCT for patients with SCID receiving a MSD.
Immune reconstitution for patients receiving MSD transplants is largely determined by SCID subtype, as noted above. In the PIDTC analysis, where over 87 % of Acute GVHD, a reaction of donor immune cells against host tissues which classically occurs within 100 days of stem cell infusion, is not uncommon in transplants for SCID. Its incidence is modified primarily by donor-recipient HLA disparity as well as the use of GVHD prophylaxis. In MSD transplants, some centers omit GVHD prophylaxis entirely, while others administer a post-transplant calcineurin inhibitor with or without methotrexate, with the rationale that GVHD is of little benefit to a patient with SCID. Although the overall incidence of acute GVHD ranges from 23 to 50 % in MSD HSCT for SCID, Grade III-IV aGVHD and chronic GVHD are uncommon even in two studies where many patients received no GVHD prophylaxis (3-6 %) [ 
Unrelated Donors
In the absence of a MSD, an URD search should be performed as soon as possible. Unrelated umbilical cord blood (UCB) sources should also be considered, and they are discussed below. Survival rates are typically lower with URD's compared to MSD's. This is likely due to a delay in proceeding to HSCT (by approximately 1-3 months) and subsequent immune reconstitution, an increased incidence of GVHD, and possibly due to increased use of chemotherapy-based conditioning. In considering an URD versus an available haploidentical donor, infection status at the time of transplant is an important determinant of survival. In infants of any age without an active infection, overall survival for URD HSCT is equivalent to that of haploidentical HSCT without conditioning (93 vs 91 % respectively) [8 •• ] . However, in the setting of an active infection at the time of transplant, overall survival for an URD HSCT is inferior compared to haploidentical HSCT without conditioning (53 vs 65 %, p = 0.006). In such cases, or when the likelihood of finding a matched URD is very low (rare ethnic background, etc.), transplantation using a haploidentical donor without conditioning should be considered as initial therapy.
Recipients of URD transplants may receive no conditioning, reduced intensity conditioning (RIC), or myeloablative conditioning, as shown in Table 2 . Overall survival appears equivalent in patients receiving URD transplants with or without conditioning. In a multicenter survey of transplants for patients with SCID (mainly IL2RG and ADA) using URD and UCB without RIC or MAC, 5-year overall survival for URD/UCB recipients was 71 %, comparable to published reports for those receiving RIC or MAC [12 • ]. In the PIDTC cohort, HSCT using adult URDs typically included conditioning, and overall survival was 74 % [8 •• ]. In a direct comparison of RIC versus MAC, a small cohort of infants with SCID (and other immunodeficiencies) receiving URD HSCT was studied: RIC was associated with 94 % overall survival, significantly better than with MAC (53 %, p = 0.014) [21] .
Overall, to determine the appropriate use of conditioning for an URD transplant, SCID type and infection risk should be considered. For patients without an intrinsic B cell defect, such as IL7Ra deficiency, there is little advantage to using conditioning; likewise, for patients with ADA deficiency or DNA repair defects, use of conditioning has been associated with poor outcomes and is not recommended [26, 27] . However, for other patients without active infection, a RIC regimen may be considered to promote B cell reconstitution, although the late effects of chemotherapy exposure in these babies have not been well characterized. For URD transplants without conditioning, acute GVHD occurs in up to 73 % of patients if serotherapy is not used, and 32 % may experience Grade III-IV aGVHD; this is reduced to 50 % (8 % with Grade III-IV) with serotherapy [12 • ]. Standard GVHD prophylaxis with a calcineurin inhibitor and methotrexate (or mycophenolate mofetil or corticosteroids in the case of UCB) is recommended for these patients. The incidence of chronic GVHD (39 %) was significantly higher in URD compared to MSD recipients (5 %; p \ 0.01) and was also partially abrogated by the use of serotherapy (47 vs 27 %).
Umbilical Cord Blood Donors
An alternative stem cell source for a SCID patient without a conventional MSD or adult URD is UCB. In one retrospective comparison of UCB vs haploidentical related donors, no difference in 5-year overall survival was detected (57 vs 62 % respectively, p = 0.68) [28] . Although this study showed increased myeloid engraftment and IVIG independence and lower rates of second transplant (for non-engraftment) in the patients receiving UCB, this may have been related to the higher-intensity conditioning that these patients received. Of note, the degree of HLA mismatch in the UCB unit was a strong determinant of inferior overall survival. The PIDTC analysis also demonstrated that for patients \3.5 months of age, UCB recipients had the lowest 5-year overall survival compared to MSD (58 %, p = 0.01) [8 •• ] . Based on these and prior studies [29] demonstrating that outcomes using a 4/6 HLAmatched UCB unit are inferior to those with a TCD haploidentical donor, this approach is only recommended when at least a 5/6 allele-matched unit is available.
Haploidentical Donors
If a MSD or a well-matched URD (adult or UCB) cannot be identified in a timely fashion, or if the patient has an active infection, a familial haploidentical transplant should be considered. As described above, survival using haploidentical donors without conditioning is comparable to that obtained with URD, unless the patient has an active infection at the time of transplant, when haploidentical HCT is superior [8 •• ] . A European retrospective analysis demonstrated equivalent survival using a T cell-depleted haploidentical relative (66 %) compared to a URD (69 %), although patients with active infection were not analyzed separately [30] .
An important parameter to consider in haploidentical transplants is the presence of transplacental maternal engraftment (TME). Maternally engrafted cells can be identified in approximately 40 % [31] of SCID patients requiring transplant and can interfere with engraftment of a paternal donor [32] . Although these maternally derived T cells are typically functionally incompetent, often expressing a limited TCR repertoire [33] with limited or no proliferative response to mitogen [34] , they can be associated with pre-transplant GVHD [32] . If TME is present without GVHD, fetal-maternal tolerance is inferred and an unconditioned maternal T cell-depleted transplant can be performed readily [13] . Engraftment is less likely if a nonmaternal donor is used without conditioning in patients with circulating maternal T cells [35] . In addition, if TME is not present, serotherapy with or without chemotherapy should be considered to try to decrease the risk of rejection due to host NK cells and/or small numbers of host T cells.
For haploidentical transplants, use of any conditioning beyond serotherapy has a significant adverse effect on overall survival when used in the context of active infections (overall survival of 65 % without conditioning vs 39 % with conditioning, p = 0.006); this difference was diminished for infants without infection (overall survival of 91 vs 81 %, p = 0.16) [8 •• ]. Therefore, withholding conditioning is appropriate in most haploidentical HCTs for SCID, especially when performed for defects in IL2RG or JAK3 [18] or when TME is present. However, without conditioning, engraftment is less likely in cases where early T cells or NK cells are present and there is no TME. For defects involving RAG1/2 or radiosensitive SCID [19, 36] graft resistance may be higher, and these patients often require some immunosuppression to achieve T cell engraftment [13] . In an attempt to promote engraftment and immune reconstitution, high CD34 cell doses without busulfan or melphalan-containing conditioning was evaluated in a single-center study [13] . Out of 15 SCID patients who received at least 20 9 10 6 CD34? cells/kg, 11 engrafted without the need for second transplant; 3-year overall survival was 87 %, although the four patients who rejected received conditioning prior to a second transplant using an URD. All patients with IL2RG deficiency or pre-HCT evidence of TME engrafted, while only three out of seven patients with NK ? SCID without TME engrafted.
T cell reconstitution in recipients of haploidentical transplants is variable. In the PIDTC study, 66 % had CD3 recovery ([1,000/mm 3 ) at 2-5 years, compared to 76 % of MSD recipients (p = 0.01) and 76 % of URD recipients (p = 0.84) [8 •• ] . Another study showed that the median time to T cell reconstitution (development of a PHA response [50 % of control) was 4.9 months, and that to development of a PHA response 90 % of control was 9.8 months [13] . This is consistent with prior studies showing that TCD is associated with a median time to regain functional T cells of 5-9 months [37, 38] .
Recovery of B cell function following haplocompatible HCT is also heterogeneous and highly dependent on SCID genotype [6, 38] . In an unconditioned cohort primarily consisting of haploidentical donors (and also including some MSDs), Buckley et al. observed long-term independence from immunoglobulin supplementation in 63 % of patients. This is comparable to results obtained by Haddad et al. in a study of only haploidentical HSCT, where conditioning was variable: 69 % of these patients recovered B cell function at last follow-up. This compares favorably to the rate of B cell reconstitution in unconditioned URD's (including UCB) where only 30 % of patients were IVIG independent at last follow-up [12 • ], although this latter result may be partly due to inclusion of only certain SCID genotypes.
The incidence of aGVHD in TCD haploidentical transplants, where no additional GVHD prophylaxis is given, ranges from 20 % (grade II-IV) to 58 % (all grade I-II) [8 •• , 13] . Chronic GVHD has been observed in up to 40 % of these patients at 6 months post-transplant, but incidence at 2 years is relatively low (13-18 %) [38] .
Toxicity
Treatment-related mortality (TRM) occurred in 26 % of patients analyzed in the PIDTC series, mostly in patients diagnosed and transplanted at [3.5 months of age, and 38 % of the mortality was due to infection [8 •• ] . However, much of the infection-related mortality seen in HSCT for SCID may be due to infections that occurred prior to diagnosis and HSCT. With the advent of NBS for SCID, TRM due to infection should decrease significantly. Pulmonary toxicity was the other primary contributor to TRM in this study, accounting for 37 % of mortality in the entire cohort, and 64 % of mortality in patients receiving MAC with busulfan-based regimens [8 •• ] . A primary risk factor for pulmonary toxicity in SCID patients is pre-existing lung infection (CMV pneumonitis, PCP pneumonia). The pulmonary toxicity of busulfan, cyclophosphamide, or fludarabine on young infants \6 months of age is not yet fully understood and requires further study [39] .
Long-term survival has increased over the last five decades among all SCID types [30, 40] . If good T cell function is achieved within 1-2 years after HSCT, function is very likely to be maintained long term [20, 41] , although some reports suggest that T cell immunity may decline over time in some patients not receiving conditioning [5] . Because longterm survival is expected for most SCID patients, late effects need to be considered carefully. At least two studies have evaluated the late effects of conditioning in SCID patients overall [41] and in patients with RAG-or Artemis-deficient SCID [42] . In the latter study, patients with radiosensitive SCID due to Artemis-deficiency had significantly more problems beyond 2 years post-transplant with growth, tooth development, and endocrinopathies when exposed to alkylating chemotherapy prior to HSCT. Organ toxicity (specifically to heart, lungs, and the central nervous system) should be monitored regularly for patients with SCID who have received chemotherapy. In patients transplanted for a variety of primary immunodeficiencies, true secondary malignancies occurred with an incidence of only 0.2 % at 5-15 years [43] . However, late mortality ([2 years post-HSCT) due to infection, organ failure, and chronic GVHD still occurred in 7 % of patients [44] .
The long-term cognitive function of SCID patients treated with HSCT is a subject of ongoing research. Cognitive effects are related to many factors, including the intrinsic genetic defect (e.g., ADA-SCID and some types of radiosensitive SCID), psychosocial factors such as socioeconomic status, the duration and severity of illness/hospitalization, and possibly direct CNS toxicity from conditioning [45, 46] . Given the general observation that the incidence and severity of cognitive deficits increases when radiation is given to very young infants [47] , alkylating chemotherapy such as busulfan, which readily crosses the blood-brain barrier, should be administered with caution. Close follow-up, including a full battery of ageappropriate neurocognitive testing, should be done biannually throughout childhood.
A diagnosis of SCID can also have significant psychosocial effects. Both the disease and the transplant process itself pose stressors to the patient and family. For example, since CMV may be transmitted through breastfeeding, mothers may be advised to discontinue breastfeeding if they are CMV-seropositive, which can be very distressing for new mothers; early cessation of breastfeeding has been associated with postpartum depression [48] . Prolonged hospitalization after initial diagnosis is sometimes necessary, especially if the home environment poses a significant infectious risk to the infant. In addition, depending on the type of transplant, the duration of hospital admission for transplant for SCID patients can be months, adding significant stress to families. The social isolation required as part of HSCT for SCID may contribute to long-term deficits in both cognitive and motor development [49] .
Conclusions
HSCT is a life-saving treatment for patients with SCID, especially if therapy is instituted early, prior to onset of Curr Pediatr Rep (2015) 3:1- 10 7 infections. Outcomes for all types of SCID have continued to steadily improve, and collaborative studies are underway that will help to further identify areas where improvement is still needed. While much progress has been made over the years to reduce side effects and improve survival, more studies are needed to address the questions that remain. For example, identifying the minimum dose of MAC that can achieve myeloid chimerism with reliable T and B cell reconstitution is especially important for patients who are otherwise unlikely to reject even a mismatched donor graft. This question is especially salient in the era of NBS, as patients are more frequently being diagnosed at \1 month of age, and would clearly benefit from immediate transplant, were it not for the potential risks posed by alkylating chemotherapy. Newer agents, such as monoclonal antibodies against CD117 (c-kit) and CD45, which target stem cells, hold the promise of allowing early HSCT without the risks of conventional chemotherapy, but need to be evaluated in prospective multicenter studies [50, 51] . In addition to refinement of conditioning approaches for newborns with SCID, the optimal GVHD prophylaxis regimen for both matched and mismatched donors requires further study, since GVHD is of little benefit to these patients, but GVHD prophylaxis can interfere with functional immune recovery. Future prospective studies of new conditioning regimens, GVHD prophylaxis strategies, and late effects will continue to refine HSCT as a therapeutic approach for patients with SCID.
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